The estimated Net Worth of Pierre Gravier is at least $1.54 Million dollars as of 16 July 2024. Pierre Gravier owns over 2,269 units of Cassava Sciences Inc stock worth over $1,463,002 and over the last few years Pierre sold SAVA stock worth over $77,191.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Pierre Gravier SAVA stock SEC Form 4 insiders trading
Pierre has made over 2 trades of the Cassava Sciences Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Pierre sold 2,269 units of SAVA stock worth $77,191 on 16 July 2024.
The largest trade Pierre's ever made was buying 7,700 units of Cassava Sciences Inc stock on 12 December 2023 worth over $198,737. On average, Pierre trades about 1,662 units every 36 days since 2023. As of 16 July 2024 Pierre still owns at least 53,531 units of Cassava Sciences Inc stock.
You can see the complete history of Pierre Gravier stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Pierre Gravier's mailing address?
Pierre's mailing address filed with the SEC is C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059.
Insiders trading at Cassava Sciences Inc
Over the last 5 years, insiders at Cassava Sciences Inc have traded over $0 worth of Cassava Sciences Inc stock and bought 1,178,376 units worth $9,853,781 . The most active insiders traders include Sanford Robertson, Richard Barry, and Patrick J Md Phd Scannon. On average, Cassava Sciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $1,235,207. The most recent stock trade was executed by Sanford Robertson on 26 April 2024, trading 69,000 units of SAVA stock currently worth $1,518,000.
What does Cassava Sciences Inc do?
refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.
What does Cassava Sciences Inc's logo look like?
Complete history of Pierre Gravier stock trades at PTC Therapeutics Inc and Cassava Sciences Inc
Cassava Sciences Inc executives and stock owners
Cassava Sciences Inc executives and other stock owners filed with the SEC include:
-
Remi Barbier,
Chairman of the Board, President, Chief Executive Officer -
Remi Barbier,
Founder, Chairman, Pres & CEO -
Nadav Friedmann,
Chief Medical and Operating Officer, Director -
Dr. Nadav Friedmann,
Chief Medical Officer & Director -
Eric J. Schoen,
Chief Financial Officer -
Eric Schoen,
Chief Financial Officer -
Sanford Robertson,
Independent Director -
Robert Gussin,
Independent Director -
Patrick Scannon,
Independent Director -
Michael O' Donnell,
Independent Director -
Dr. James W. Kupiec M.D.,
Chief Clinical Devel. Officer -
Dr. Lindsay H. Burns Ph.D.,
Sr. VP of Neuroscience -
Dr. Michael Marsman,
Sr. VP of Regulatory Affairs -
Michael Zamloot,
Sr. VP of Technical Operations -
Dr. George Thornton,
Sr. VP of Technology -
Saira Ramasastry,
Director -
Pierre Gravier,
Director -
Claude Nicaise,
Director -
Robert Christopher Cook,
SVP & General Counsel -
Richard Barry,
Director -
James William Kupiec,
Chief Medical Officer -
Robert Eugene Jr Anderson,
Director